Home Cart 0 Sign in  

[ CAS No. 75884-70-7 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 75884-70-7
Chemical Structure| 75884-70-7
Structure of 75884-70-7 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 75884-70-7 ]

Related Doc. of [ 75884-70-7 ]

Alternatived Products of [ 75884-70-7 ]

Product Details of [ 75884-70-7 ]

CAS No. :75884-70-7 MDL No. :MFCD09264003
Formula : C8H5BrN2O Boiling Point : -
Linear Structure Formula :- InChI Key :QMONLZVJOOMKRW-UHFFFAOYSA-N
M.W : 225.04 Pubchem ID :11535918
Synonyms :

Calculated chemistry of [ 75884-70-7 ]

Physicochemical Properties

Num. heavy atoms : 12
Num. arom. heavy atoms : 10
Fraction Csp3 : 0.0
Num. rotatable bonds : 0
Num. H-bond acceptors : 3.0
Num. H-bond donors : 1.0
Molar Refractivity : 49.26
TPSA : 46.01 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.42 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.8
Log Po/w (XLOGP3) : 1.76
Log Po/w (WLOGP) : 2.1
Log Po/w (MLOGP) : 1.95
Log Po/w (SILICOS-IT) : 2.13
Consensus Log Po/w : 1.95

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.96
Solubility : 0.246 mg/ml ; 0.00109 mol/l
Class : Soluble
Log S (Ali) : -2.34
Solubility : 1.02 mg/ml ; 0.00453 mol/l
Class : Soluble
Log S (SILICOS-IT) : -3.61
Solubility : 0.0549 mg/ml ; 0.000244 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.99

Safety of [ 75884-70-7 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H332-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 75884-70-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 75884-70-7 ]
  • Downstream synthetic route of [ 75884-70-7 ]

[ 75884-70-7 ] Synthesis Path-Upstream   1~6

  • 1
  • [ 102126-71-6 ]
  • [ 75884-70-7 ]
YieldReaction ConditionsOperation in experiment
87%
Stage #1: at 90℃; for 1.5 h;
Stage #2: With hydrazine In isopropyl alcohol
134C (954 mg, 4.17 mmol) was suspended in isopropyl alcohol (10 mL). The solution was heated at 90° C. for 1.5 h. Hydrazine monohydrate (0.4 mL, 8.25 mmol) was added in 4 increments. The resulting suspension was filtered and washed with isopropyl alcohol to give 134D (813 mg, 87percent) as a beige solid. LC-MS m/z: 227.12 (M+H)+.
Reference: [1] Patent: US2007/3539, 2007, A1, . Location in patent: Page/Page column 105
[2] Patent: US4769369, 1988, A,
  • 2
  • [ 573675-39-5 ]
  • [ 75884-70-7 ]
YieldReaction ConditionsOperation in experiment
46.6% at 95℃; for 5 h; 6-Bromo-2H-phthalazin-l -one; A mixture of 5-bromo-3-hydroxy-2,3-dihydro-isoindol-l-one (15.75 g, 69.06 mmol) and hydrazine hydrate (70 mL, 1439.2 mmol) was heated at 95 0C for 5 h. The precipitate was filtered, washed with water and the crude material triturated with hot EtOAc to afford the product (7.25 g, 46.6 percent) as a yellow solid.
0.5 g With hydrazine hydrate In water at 95℃; for 5 h; To a stirred solution of 5-bromo-3-hydroxyisoindoline-1-one (1.0 g, 4.40 mmol) in water, was added hydrazine hydrate (0.45 g, 8.80 mmol) and heated to 95° C. for 5 h. The reaction mixture was cooled to ambient temperature, filtered and washed with diethyl ether and pentane (1:1) to afford the title compound as a white solid that was used in the next step without further purification (0.5 g): ESIMS m/z 225.15 ([M+H]+).
0.5 g With hydrazine hydrate In water at 95℃; for 5 h; To a stirred solution of 5-bromo-3- hydroxyisoindoline-1-one (1.0 g, 4.40 mmol) in water, was added hydrazine hydrate (0.45 g , 8.80 mmol) and heated to 95°C for 5 h. The reaction mixture was cooled to RT, filtered and washed with diethyl ether and pentane (1: 1) to afford the title compound as a white solid that was used in the next step without further purification (0.5 g): ESIMS m/z 225.15 ([M+H]+).
Reference: [1] Patent: WO2008/61108, 2008, A2, . Location in patent: Page/Page column 55
[2] Journal of Medicinal Chemistry, 2006, vol. 49, # 13, p. 3753 - 3756
[3] Patent: US2012/329649, 2012, A1, . Location in patent: Page/Page column 49
[4] Patent: US2014/171314, 2014, A1, . Location in patent: Page/Page column
[5] Patent: WO2014/100163, 2014, A1, . Location in patent: Page/Page column 92
[6] Patent: US2014/171308, 2014, A1, . Location in patent: Paragraph 0439
[7] Patent: US2014/171312, 2014, A1, . Location in patent: Paragraph 0605
[8] Patent: WO2014/100206, 2014, A1, . Location in patent: Page/Page column 93
[9] Patent: US9211280, 2015, B2, . Location in patent: Page/Page column 93
  • 3
  • [ 102126-70-5 ]
  • [ 75884-70-7 ]
YieldReaction ConditionsOperation in experiment
73% With hydrazine hydrate In ethanol for 1.5 h; Reflux j0201] 6-l3romophthalazin-1(2H)-one (22b) In a 25 mE round bottom flask was dissolved 3,5-dibromoisobenzoth- ran-1(3H)-one (302 mg, 1.04 mmol) in ethanol (10 mE). Hydrazine monohydrate (0.25 mE, 5.18 mmol) was then added via a syringe and the solution was refluxed for 1.5 hours. The solution was cooled to room temperature and ice water (30 mE) was added to the reaction mixture. The precipitate was vacuum filtered and dried under a vacuum overnight to yield 22b as a white solid in 73percent yield. ‘H NMR (500 MHz, DMSO-d5) ö 12.78 (br. s., 1H), 8.33 (s, 1H), 8.23 (d, J=2.0 Hz, 1H), 8.12 (d, J=8.3 Hz, 1H), 8.00 (dd, J=8.3, 2.0 Hz, 1H). ECMS found 224.9 [M+H].
Reference: [1] Patent: US2015/259331, 2015, A1, . Location in patent: Paragraph 0201
[2] Journal of Medicinal Chemistry, 2015, vol. 58, # 14, p. 5522 - 5537
  • 4
  • [ 6941-75-9 ]
  • [ 75884-70-7 ]
Reference: [1] Journal of Medicinal Chemistry, 2006, vol. 49, # 13, p. 3753 - 3756
[2] Patent: US2012/329649, 2012, A1,
[3] Patent: US2014/171314, 2014, A1,
[4] Patent: WO2014/100163, 2014, A1,
[5] Patent: US2014/171308, 2014, A1,
[6] Patent: WO2014/100206, 2014, A1,
[7] Patent: US2014/171312, 2014, A1,
[8] Patent: US9211280, 2015, B2,
  • 5
  • [ 64169-34-2 ]
  • [ 75884-70-7 ]
Reference: [1] Journal of Medicinal Chemistry, 2015, vol. 58, # 14, p. 5522 - 5537
[2] Patent: US2015/259331, 2015, A1,
  • 6
  • [ 99548-55-7 ]
  • [ 75884-70-7 ]
Reference: [1] Patent: CN107879975, 2018, A,
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 75884-70-7 ]

Bromides

Chemical Structure| 1379338-09-6

[ 1379338-09-6 ]

7-Bromocinnolin-3-ol

Similarity: 0.88

Chemical Structure| 7364-27-4

[ 7364-27-4 ]

5-Bromo-1H-indazol-3-ol

Similarity: 0.86

Chemical Structure| 885521-92-6

[ 885521-92-6 ]

6-Bromo-1H-indazol-3-ol

Similarity: 0.84

Chemical Structure| 887578-57-6

[ 887578-57-6 ]

7-Bromo-1H-indazol-3-ol

Similarity: 0.81

Chemical Structure| 885518-58-1

[ 885518-58-1 ]

4,6-Dibromo-1H-indazol-3-ol

Similarity: 0.79

Alcohols

Chemical Structure| 1379338-09-6

[ 1379338-09-6 ]

7-Bromocinnolin-3-ol

Similarity: 0.88

Chemical Structure| 7364-27-4

[ 7364-27-4 ]

5-Bromo-1H-indazol-3-ol

Similarity: 0.86

Chemical Structure| 885521-92-6

[ 885521-92-6 ]

6-Bromo-1H-indazol-3-ol

Similarity: 0.84

Chemical Structure| 887578-57-6

[ 887578-57-6 ]

7-Bromo-1H-indazol-3-ol

Similarity: 0.81

Chemical Structure| 885518-58-1

[ 885518-58-1 ]

4,6-Dibromo-1H-indazol-3-ol

Similarity: 0.79

Related Parent Nucleus of
[ 75884-70-7 ]

Phthalazines

Chemical Structure| 19064-74-5

[ 19064-74-5 ]

6-Bromophthalazine

Similarity: 0.71